bluebird bio Stock Price, News & Analysis (NASDAQ:BLUE)

$200.20 5.55 (2.85 %)
(As of 01/24/2018 04:45 AM ET)
Previous Close$194.65
Today's Range$188.55 - $200.80
52-Week Range$64.65 - $222.03
Volume1.59 million shs
Average Volume767,663 shs
Market Capitalization$9.54 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.08

About bluebird bio (NASDAQ:BLUE)

bluebird bio logobluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Receive BLUE News and Ratings via Email

Sign-up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BLUE
CUSIPN/A
Phone339-499-9300

Debt

Debt-to-Equity RatioN/A
Current Ratio9.88%
Quick Ratio9.88%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.16 million
Price / Sales1,593.48
Cash FlowN/A
Price / CashN/A
Book Value$21.42 per share
Price / Book9.35

Profitability

Trailing EPS($7.02)
Net Income$-263,500,000.00
Net Margins-883.18%
Return on Equity-28.79%
Return on Assets-22.94%

Miscellaneous

Employees328
Outstanding Shares49,030,000

bluebird bio (NASDAQ:BLUE) Frequently Asked Questions

What is bluebird bio's stock symbol?

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

How were bluebird bio's earnings last quarter?

bluebird bio Inc (NASDAQ:BLUE) released its quarterly earnings data on Wednesday, November, 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.68) by $0.05. The biotechnology company earned $7.71 million during the quarter, compared to the consensus estimate of $8.47 million. bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The business's revenue was up 397.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($2.07) EPS. View bluebird bio's Earnings History.

When will bluebird bio make its next earnings announcement?

bluebird bio is scheduled to release their next quarterly earnings announcement on Tuesday, February, 20th 2018. View Earnings Estimates for bluebird bio.

Where is bluebird bio's stock going? Where will bluebird bio's stock price be in 2018?

22 analysts have issued 12 month price objectives for bluebird bio's shares. Their predictions range from $71.00 to $242.00. On average, they expect bluebird bio's share price to reach $159.53 in the next year. View Analyst Ratings for bluebird bio.

What are Wall Street analysts saying about bluebird bio stock?

Here are some recent quotes from research analysts about bluebird bio stock:

  • 1. Cantor Fitzgerald analysts commented, "Renewed Confidence in SCD. We believe the longer-term HbA T87Q response of 6.4g/dL and 3.0g/dL achieved in Group B patients validates the improved process’ potential to address SCD. While long-term questions remain, especially as they pertain to sourcing of the drug product from peripheral blood, the updated clinical data lift a key uncertainty on the ability to achieve sufficient vector copy number (VCN) in peripheral blood translating into adequate healthy hemoglobin production, Additionally, the first Group C patient treated with an improved drug product and optimized cell source has demonstrated initial 1-month peripheral VCN of 2.5 copies/diploid, resembling results of the better performing Group B patient." (12/11/2017)
  • 2. Maxim Group analysts commented, "The approvals of Yescarta and Kymriah combined with Gilead’s acquisition of Kite have ushered in a paradigm shift in oncology. T- cell therapies (CAR- T, TCR, other) are here to stay. We attended the GE Manufacturing summit in Beijing (Cell Therapy Regulatory & Technology") earlier this month and it became evident that manufacturing obstacles will be overcome. The days of Dendreon’s debacle are long past. Remember too that gene therapy is not far behind as Spark’s Luxterna is expected to be approved in January 2018 with a seven-figure price tag." (11/30/2017)
  • 3. Morgan Stanley analysts commented, "excitement." But now may be a time for investors to turn cautious, at least according to analysts at Morgan Stanley. The firm's Matthew Harrison downgraded Bluebird's stock rating from Equal Weight to Underweight with an unchanged $105 price target.Heading into the end of 2017 there are underappreciated risks that the Street may be ignoring, Harrison commented. Specifically, data related to LentiGlobin sickle cell data is unlikely to show any significant improvement in hemoglobin production that will be good enough to "increase investor confidence" in its sickle cell gene therapy."Based on prior data, our premise is that to improve hemoglobin production in sickle cell patients, the correlation between drug-product vector copy number (DP VCN) and peripheral VCN (pVCN) needs to increase substantially," the analyst explained. "We do not believe the evidence supports current investor optimism that this can be solved by ASH." (10/2/2017)
  • 4. According to Zacks Investment Research, "Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. " (7/18/2017)
  • 5. BTIG Research analysts commented, "generally captured" data updates from ASCO and EHA. Positive On Outlook But Not Enough To Remain BullishMeanwhile, Bluebird has a "good lead" over the competition in drugs targeting anti-BCMA and a Phase 1 study of bb21217 will commence in the bottom half of 2017. But at the same time competitive efforts from rivals will also ramp up, including Kite Pharma Inc (NASDAQ: KITE), which will begin a study of a fully-human anti-BCMA CAR T therapy in the third quarter.The analyst remains "more optimistic than most" regarding the LentiGlobin program for Beta-thalassemia and Sickle-cell disease. Also, the company's broadening of its oncology efforts may be a source of concern among some investors but early success in bb2121 is indeed supportive of a "broader effort in larger markets with better defined patient populations." (6/30/2017)

Who are some of bluebird bio's key competitors?

Who are bluebird bio's key executives?

bluebird bio's management team includes the folowing people:

  • Daniel S. Lynch, Independent Chairman of the Board (Age 59)
  • Nick Leschly, President, Chief Executive Officer, Director (Age 44)
  • Jeffrey T. Walsh, Chief Financial Officer, Principal Financial Officer and Strategy Officer (Age 51)
  • Susanna Gatti High, Chief Operating Officer (Age 49)
  • Kory J. Wentworth, Principal Accounting Officer, Vice President - Finance (Age 39)
  • Philip D. Gregory Ph.D., Chief Scientific Officer (Age 46)
  • David M. Davidson M.D., Chief Medical Officer (Age 53)
  • Jason F. Cole Esq., Chief Legal Officer, Secretary (Age 44)
  • John O. Agwunobi M.D., Director (Age 52)
  • Mary Lynne Hedley Ph.D., Director (Age 54)

Who owns bluebird bio stock?

bluebird bio's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.60%), Frontier Capital Management Co. LLC (0.20%), Westpac Banking Corp (0.07%), Rothschild Investment Corp IL (0.02%), Strs Ohio (0.02%) and Creative Planning (0.00%). Company insiders that own bluebird bio stock include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Institutional Ownership Trends for bluebird bio.

Who sold bluebird bio stock? Who is selling bluebird bio stock?

bluebird bio's stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Bank of Montreal Can and Winslow Evans & Crocker Inc.. Company insiders that have sold bluebird bio company stock in the last year include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Insider Buying and Selling for bluebird bio.

Who bought bluebird bio stock? Who is buying bluebird bio stock?

bluebird bio's stock was bought by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc., Rothschild Investment Corp IL, Westpac Banking Corp, Creative Planning, Steward Partners Investment Advisory LLC and Strs Ohio. View Insider Buying and Selling for bluebird bio.

How do I buy bluebird bio stock?

Shares of bluebird bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is bluebird bio's stock price today?

One share of bluebird bio stock can currently be purchased for approximately $200.20.

How big of a company is bluebird bio?

bluebird bio has a market capitalization of $9.54 billion and generates $6.16 million in revenue each year. The biotechnology company earns $-263,500,000.00 in net income (profit) each year or ($7.02) on an earnings per share basis. bluebird bio employs 328 workers across the globe.

How can I contact bluebird bio?

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]


MarketBeat Community Rating for bluebird bio (BLUE)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  640 (Vote Outperform)
Underperform Votes:  250 (Vote Underperform)
Total Votes:  890
MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

bluebird bio (NASDAQ:BLUE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldBuy
Consensus Rating Score: 2.502.502.452.50
Ratings Breakdown: 2 Sell Rating(s)
7 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
7 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $159.53$159.53$118.86$99.45
Price Target Upside: 6.02% downside13.93% downside9.75% downside0.05% downside

bluebird bio (NASDAQ:BLUE) Consensus Price Target History

Price Target History for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ:BLUE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/9/2018OppenheimerReiterated RatingHoldLowView Rating Details
12/21/2017CIBCInitiated CoverageMarket Perform -> Market PerformHighView Rating Details
12/13/2017Maxim GroupDowngradeBuy -> Hold$200.00MediumView Rating Details
12/13/2017BarclaysReiterated RatingOverweight -> Overweight$162.00 -> $209.00HighView Rating Details
12/12/2017SunTrust BanksBoost Price TargetBuy$223.00HighView Rating Details
12/12/2017Wells Fargo & CoReiterated RatingOutperform$190.00 -> $242.00HighView Rating Details
12/11/2017BMO Capital MarketsSet Price TargetBuy$215.00HighView Rating Details
12/11/2017Jefferies GroupUpgradeHold -> Buy$130.00 -> $211.00HighView Rating Details
12/11/2017Cantor FitzgeraldSet Price TargetUnderweight -> Underweight$58.00 -> $113.00HighView Rating Details
12/5/2017Canaccord GenuityInitiated CoverageBuy -> Buy$202.00LowView Rating Details
11/3/2017Morgan StanleyUpgradeUnderweight -> Equal WeightN/AView Rating Details
11/2/2017WedbushReiterated RatingOutperform$135.00 -> $174.00N/AView Rating Details
11/2/2017BTIG ResearchUpgradeNeutral -> Buy$177.00N/AView Rating Details
11/1/2017Leerink SwannReiterated RatingOutperform$145.00 -> $162.00N/AView Rating Details
10/16/2017Evercore ISIUpgradeIn-Line -> Outperform$102.00N/AView Rating Details
10/6/2017Goldman Sachs GroupReiterated RatingBuy -> Buy$186.00N/AView Rating Details
8/31/2017CowenReiterated RatingOutperformHighView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$109.00HighView Rating Details
6/26/2017Janney Montgomery ScottSet Price TargetBuy$125.00N/AView Rating Details
6/16/2017Standpoint ResearchReiterated RatingBuy -> Reduce$110.00LowView Rating Details
6/5/2017Bank of AmericaReiterated RatingHold$95.00HighView Rating Details
2/23/2017Roth CapitalSet Price TargetHold$71.00N/AView Rating Details
12/7/2016JPMorgan Chase & Co.Reiterated RatingBuy$120.00N/AView Rating Details
11/30/2016Piper Jaffray CompaniesReiterated RatingOverweight$95.00N/AView Rating Details
(Data available from 1/24/2016 forward)

Earnings

bluebird bio (NASDAQ:BLUE) Earnings History and Estimates Chart

Earnings by Quarter for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ BLUE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/20/2018($1.68)N/AView Earnings Details
11/1/2017Q3 2017($1.68)($1.73)$8.47 million$7.71 millionViewN/AView Earnings Details
8/2/2017Q2 2017($1.66)($1.73)$6.29 million$16.70 millionViewN/AView Earnings Details
5/3/2017Q1 2017($1.76)($1.68)$1.51 million$6.83 millionViewN/AView Earnings Details
2/22/2017Q4 2016($1.86)($1.88)$1.76 million$1.55 millionViewN/AView Earnings Details
11/2/2016Q3 2016($1.59)($2.07)$1.82 million$1.55 millionViewN/AView Earnings Details
8/3/2016Q2($1.44)($1.59)$2.01 million$1.55 millionViewN/AView Earnings Details
5/4/2016Q1($1.23)($1.52)$4.50 million$1.50 millionViewN/AView Earnings Details
2/24/2016Q4($1.11)($1.29)$3.21 million$1.47 millionViewN/AView Earnings Details
11/4/2015Q3($0.96)($1.18)$5.63 million$1.30 millionViewListenView Earnings Details
8/6/2015Q215($0.78)($1.57)$8.60 million$4.94 millionViewN/AView Earnings Details
5/6/2015Q115($0.68)($0.76)$6.20 million$6.30 millionViewN/AView Earnings Details
2/25/2015Q414($0.62)($0.66)$6.20 million$6.30 millionViewN/AView Earnings Details
11/12/2014Q314($0.52)($0.61)$6.20 million$6.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.45)($0.06)$6.15 million$6.30 millionViewN/AView Earnings Details
5/13/2014Q114($0.32)($0.44)$6.23 million$6.30 millionViewN/AView Earnings Details
3/5/2014($0.31)($0.34)ViewN/AView Earnings Details
11/12/2013Q3($0.25)($0.26)$5.59 million$6.39 millionViewN/AView Earnings Details
8/8/2013Q213($0.35)($2.13)$4.85 million$6.30 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

bluebird bio (NASDAQ:BLUE) Earnings Estimates

2018 EPS Consensus Estimate: ($6.94)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.70)($1.68)($1.69)
Q2 20182($1.73)($1.66)($1.70)
Q3 20182($1.77)($1.73)($1.75)
Q4 20182($1.85)($1.76)($1.81)
Q1 20191($1.96)($1.96)($1.96)
Q2 20191($2.10)($2.10)($2.10)
Q3 20191($1.71)($1.71)($1.71)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for bluebird bio (NASDAQ:BLUE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

bluebird bio (NASDAQ BLUE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.90%
Insider Trades by Quarter for bluebird bio (NASDAQ:BLUE)
Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

bluebird bio (NASDAQ BLUE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/8/2018David DavidsonInsiderSell3,522$173.61$611,454.4213,959View SEC Filing  
1/5/2018Jason ColeInsiderSell1,129$173.38$195,746.0219,945View SEC Filing  
1/5/2018Nick LeschlyCEOSell5,435$173.38$942,320.30171,009View SEC Filing  
1/3/2018David DavidsonInsiderSell6,000$180.30$1,081,800.0021,977View SEC Filing  
12/13/2017Nick LeschlyInsiderSell117,500$184.08$21,629,400.00293,232View SEC Filing  
12/11/2017Jeffrey T WalshInsiderSell9,900$216.54$2,143,746.0037,205View SEC Filing  
12/11/2017Mark VachonDirectorSell7,000$216.64$1,516,480.008,000View SEC Filing  
12/1/2017Philip D GregoryInsiderSell2,250$172.54$388,215.0028,734View SEC Filing  
12/1/2017Susanna Gatti HighCOOSell1,282$172.15$220,696.3013,718View SEC Filing  
11/10/2017Jeffrey T WalshInsiderSell9,900$149.58$1,480,842.0028,798View SEC Filing  
11/1/2017Jeffrey T WalshInsiderSell35,000$151.38$5,298,300.0062,305View SEC Filing  
11/1/2017Nick LeschlyCEOSell2,127$145.17$308,776.59257,486View SEC Filing  
10/23/2017Nick LeschlyInsiderSell7,050$145.14$1,023,237.00259,059View SEC Filing  
10/20/2017Nick LeschlyCEOSell3,350$145.02$485,817.00259,059View SEC Filing  
10/17/2017Nick LeschlyCEOSell10,823$145.05$1,569,876.15262,409View SEC Filing  
10/10/2017Jeffrey T WalshInsiderSell4,900$129.94$636,706.00View SEC Filing  
10/2/2017David DavidsonInsiderSell4,000$131.31$525,240.00View SEC Filing  
9/14/2017John MaraganoreDirectorSell18,868$131.21$2,475,670.2824,711View SEC Filing  
9/12/2017Mark VachonDirectorSell6,000$126.82$760,920.008,000View SEC Filing  
9/11/2017Jeffrey T WalshInsiderSell4,900$125.73$616,077.0032,205View SEC Filing  
9/1/2017Nick LeschlyInsiderSell46,833$122.27$5,726,270.91289,368View SEC Filing  
8/31/2017Daniel LynchDirectorSell500$120.00$60,000.003,300View SEC Filing  
8/31/2017Jeffrey T WalshInsiderSell12,000$125.01$1,500,120.0039,305View SEC Filing  
8/30/2017Nick LeschlyInsiderSell25,667$115.18$2,956,325.06339,368View SEC Filing  
8/28/2017Jeffrey T WalshInsiderSell1,250$107.06$133,825.0028,555View SEC Filing  
8/14/2017James MandellDirectorSell1,000$95.95$95,950.001,000View SEC Filing  
8/10/2017Jeffrey T WalshInsiderSell1,250$95.41$119,262.5028,555View SEC Filing  
8/7/2017Philip D GregoryInsiderSell750$99.00$74,250.0031,234View SEC Filing  
8/4/2017Eric SullivanInsiderSell861$93.83$80,787.635,924View SEC Filing  
8/1/2017David DavidsonInsiderSell3,000$92.37$277,110.0018,977View SEC Filing  
7/10/2017Jeffrey T WalshInsiderSell2,500$99.89$249,725.0029,805View SEC Filing  
7/7/2017David DavidsonInsiderSell1,200$100.49$120,588.0016,077View SEC Filing  
7/6/2017Philip D GregoryInsiderSell2,250$103.83$233,617.5033,734View SEC Filing  
7/5/2017David DavidsonInsiderSell5,000$105.28$526,400.0022,177View SEC Filing  
6/29/2017Eric SullivanInsiderSell6,787$108.96$739,511.528,466View SEC Filing  
6/27/2017Nick LeschlyInsiderSell25,000$108.05$2,701,250.00360,656View SEC Filing  
6/23/2017Daniel LynchDirectorSell4,000$109.09$436,360.004,808View SEC Filing  
6/20/2017Daniel LynchDirectorSell2,500$120.03$300,075.005,300View SEC Filing  
6/7/2017Jason ColeInsiderSell17,245$100.22$1,728,293.9030,871View SEC Filing  
6/6/2017Daniel LynchDirectorSell2,263$100.14$226,616.823,663View SEC Filing  
6/6/2017Philip D GregoryInsiderSell1,500$99.04$148,560.0037,279View SEC Filing  
6/5/2017David DavidsonInsiderSell1,000$90.00$90,000.0018,177View SEC Filing  
5/25/2017Daniel LynchDirectorSell2,000$80.00$160,000.003,400View SEC Filing  
4/27/2017Daniel LynchDirectorSell1,000$90.01$90,010.002,400View SEC Filing  
4/25/2017Daniel LynchDirectorSell2,000$86.75$173,500.003,400View SEC Filing  
4/10/2017Jeffrey T WalshInsiderSell1,250$87.38$109,225.0028,555View SEC Filing  
4/3/2017David DavidsonInsiderSell3,000$90.89$272,670.0020,177View SEC Filing  
3/27/2017Daniel LynchDirectorSell3,000$88.12$264,360.003,400View SEC Filing  
3/16/2017Daniel LynchDirectorSell237$100.07$23,716.591,637View SEC Filing  
3/16/2017Jason ColeInsiderSell4,930$100.07$493,345.1016,981View SEC Filing  
3/3/2017John MaraganoreDirectorSell13,839$85.02$1,176,591.785,765View SEC Filing  
2/15/2017Daniel LynchDirectorSell150$80.22$12,033.001,550View SEC Filing  
2/15/2017Jason ColeInsiderSell666$80.22$53,426.5212,051View SEC Filing  
2/14/2017Daniel LynchDirectorSell850$80.01$68,008.502,250View SEC Filing  
2/14/2017Jason ColeInsiderSell3,772$80.01$301,797.7212,717View SEC Filing  
1/31/2017James MandellDirectorSell8,000$75.04$600,320.009,000View SEC Filing  
1/27/2017Daniel LynchDirectorSell1,000$70.09$70,090.002,400View SEC Filing  
1/27/2017David DavidsonInsiderSell6,000$69.02$414,120.0014,677View SEC Filing  
1/5/2017Jason ColeInsiderSell549$67.10$36,837.909,389View SEC Filing  
10/3/2016Eric SullivanInsiderSell416$67.00$27,872.005,891View SEC Filing  
9/13/2016Eric SullivanInsiderSell416$59.00$24,544.005,891View SEC Filing  
8/3/2016Eric SullivanInsiderSell416$59.00$24,544.005,891View SEC Filing  
7/27/2016Eric SullivanInsiderSell2,912$55.01$160,189.124,456View SEC Filing  
7/20/2016Eric SullivanInsiderSell2,807$45.04$126,427.284,656View SEC Filing  
7/15/2016David DavidsonInsiderSell1,000$45.08$45,080.0010,600View SEC Filing  
6/16/2016Philip D GregoryInsiderSell2,931$39.52$115,833.1230,069View SEC Filing  
6/15/2016David DavidsonInsiderSell1,000$40.11$40,110.0010,600View SEC Filing  
5/16/2016David DavidsonInsiderSell1,000$38.73$38,730.0010,600View SEC Filing  
4/15/2016David DavidsonInsiderSell1,000$49.63$49,630.0010,600View SEC Filing  
3/15/2016David DavidsonInsiderSell1,000$46.13$46,130.0010,600View SEC Filing  
2/16/2016David DavidsoninsiderSell1,000$45.18$45,180.001,000View SEC Filing  
1/15/2016David DavidsoninsiderSell1,000$44.39$44,390.00View SEC Filing  
12/15/2015David DavidsoninsiderSell1,000$58.55$58,550.00View SEC Filing  
12/8/2015Nick LeschlyCEOBuy9,682$51.75$501,043.50313,241View SEC Filing  
11/16/2015David DavidsoninsiderSell2,000$70.99$141,980.00View SEC Filing  
11/10/2015Jeffrey T. WalshCOOSell11,000$74.60$820,600.00View SEC Filing  
10/15/2015David DavidsoninsiderSell2,000$79.70$159,400.00View SEC Filing  
10/12/2015Jeffrey T. WalshCOOSell11,000$88.06$968,660.00View SEC Filing  
10/9/2015Jason ColeSVPSell5,000$86.91$434,550.00View SEC Filing  
10/5/2015Daniel LynchDirectorSell3,000$100.41$301,230.00View SEC Filing  
9/17/2015Daniel LynchDirectorSell1,500$140.06$210,090.00View SEC Filing  
9/15/2015David DavidsoninsiderSell2,000$129.98$259,960.00View SEC Filing  
9/10/2015Jeffrey T. WalshCOOSell11,000$130.02$1,430,220.00View SEC Filing  
9/9/2015Jason ColeSVPSell2,000$136.56$273,120.00View SEC Filing  
9/8/2015Daniel LynchDirectorSell7,000$132.75$929,250.00View SEC Filing  
9/8/2015Nick LeschlyCEOSell125,000$135.24$16,905,000.00246,521View SEC Filing  
9/1/2015James MandellDirectorSell1,500$125.96$188,940.00View SEC Filing  
7/20/2015Eric SullivanInsiderSell1,126$163.36$183,943.36View SEC Filing  
7/15/2015David DavidsonInsiderSell2,000$165.96$331,920.00View SEC Filing  
7/10/2015Jeffrey T WalshCOOSell11,000$158.63$1,744,930.00View SEC Filing  
7/9/2015Jason ColeSVPSell5,000$158.19$790,950.00View SEC Filing  
6/15/2015David DavidsonInsiderSell2,000$183.34$366,680.00View SEC Filing  
6/10/2015Jeffrey T WalshCOOSell11,000$179.70$1,976,700.00View SEC Filing  
6/1/2015Mitchell H FinerInsiderSell15,000$190.25$2,853,750.00View SEC Filing  
4/20/2015Mitchell H FinerInsiderSell15,000$126.03$1,890,450.00View SEC Filing  
4/15/2015David DavidsonInsiderSell2,000$130.18$260,360.00View SEC Filing  
4/10/2015Jeffrey T WalshCOOSell21,000$126.21$2,650,410.00View SEC Filing  
4/2/2015Eric SullivanInsiderSell2,998$117.81$353,194.38View SEC Filing  
3/10/2015Jeffrey T WalshCOOSell10,500$110.06$1,155,630.00View SEC Filing  
3/2/2015David DavidsonInsiderSell4,000$94.84$379,360.00View SEC Filing  
1/12/2015Jeffrey T WalshCOOSell10,500$103.57$1,087,485.00View SEC Filing  
1/2/2015David DavidsonInsiderSell4,000$90.01$360,040.00View SEC Filing  
12/19/2014John MaraganoreDirectorBuy2,352$85.00$199,920.00View SEC Filing  
12/10/2014Jeffrey T WalshCOOSell43,500$78.06$3,395,610.00View SEC Filing  
12/8/2014David DavidsonInsiderSell15,000$46.10$691,500.00View SEC Filing  
12/3/2014David DavidsonInsiderSell3,000$41.65$124,950.00View SEC Filing  
12/1/2014Mitchell H FinerInsiderSell18,000$39.70$714,600.00View SEC Filing  
12/1/2014Nick LeschlyCEOSell2,417$39.70$95,954.90View SEC Filing  
11/3/2014David DavidsonInsiderSell3,000$41.68$125,040.00View SEC Filing  
11/3/2014Nick LeschlyCEOSell25,000$41.68$1,042,000.00View SEC Filing  
10/24/2014Nick LeschlyCEOSell33,900$40.22$1,363,458.00View SEC Filing  
10/10/2014Jeffrey T WalshCOOSell7,500$33.16$248,700.00View SEC Filing  
10/9/2014Steven GillisDirectorSell115,000$35.25$4,053,750.00View SEC Filing  
10/8/2014Mitchell H FinerInsiderSell34,518$33.52$1,157,043.36View SEC Filing  
10/7/2014Steven GillisDirectorSell57,435$35.43$2,034,922.05View SEC Filing  
10/2/2014Steven GillisDirectorSell91,165$35.28$3,216,301.20View SEC Filing  
10/1/2014David DavidsonInsiderSell3,000$34.55$103,650.00View SEC Filing  
10/1/2014Nick LeschlyCEOSell8,000$34.55$276,400.00View SEC Filing  
9/12/2014Robert I TepperDirectorSell125,000$36.54$4,567,500.00View SEC Filing  
9/10/2014Jeffrey T WalshCOOSell7,500$37.02$277,650.00View SEC Filing  
9/2/2014David DavidsonInsiderSell3,000$38.00$114,000.00View SEC Filing  
9/2/2014Nick LeschlyCEOSell10,300$38.45$396,035.00View SEC Filing  
8/11/2014Jeffrey T WalshCOOSell7,500$34.26$256,950.00View SEC Filing  
8/1/2014David DavidsonInsiderSell3,000$33.62$100,860.00View SEC Filing  
8/1/2014Nick LeschlyCEOSell8,000$33.62$268,960.00View SEC Filing  
7/14/2014John MaraganoreDirectorBuy2,941$34.00$99,994.00View SEC Filing  
7/10/2014Jeffrey T WalshCOOSell7,500$33.20$249,000.00View SEC Filing  
7/3/2014Nick LeschlyCEOSell22,283$39.86$888,200.38View SEC Filing  
7/1/2014David DavidsonInsiderSell3,000$39.55$118,650.00View SEC Filing  
6/20/2014Nick LeschlyCEOSell17,075$40.06$684,024.50View SEC Filing  
6/16/2014Jeffrey T WalshCOOSell1,500$39.86$59,790.00View SEC Filing  
6/16/2014Mitchell H FinerInsiderSell10,000$39.84$398,400.00View SEC Filing  
6/16/2014Nick LeschlyCEOSell42,925$40.02$1,717,858.50View SEC Filing  
6/10/2014Jeffrey T WalshCOOSell6,000$24.23$145,380.00View SEC Filing  
6/2/2014Mitchell H FinerInsiderSell8,000$22.21$177,680.00View SEC Filing  
6/2/2014Nick LeschlyCEOSell5,000$22.21$111,050.00View SEC Filing  
5/14/2014Jeffrey WalshCOOSell1,500$20.03$30,045.00View SEC Filing  
5/12/2014Jeffrey WalshCOOSell4,500$18.93$85,185.00View SEC Filing  
5/1/2014David DavidsonInsiderSell4,000$19.85$79,400.00View SEC Filing  
5/1/2014Nick LeschlyCEOSell5,000$20.07$100,350.00304,318View SEC Filing  
4/10/2014Jeffrey WalshCOOSell6,000$21.29$127,740.00View SEC Filing  
1/22/2014Linda BainVPSell2,500$25.11$62,775.00View SEC Filing  
1/17/2014Robert TepperDirectorSell307,000$22.43$6,886,010.00View SEC Filing  
1/16/2014Mitchell FinerInsiderSell10,000$23.52$235,200.00View SEC Filing  
1/14/2014Robert TepperDirectorSell340,000$21.90$7,446,000.00View SEC Filing  
1/10/2014Jeffrey WalshCOOSell6,000$21.98$131,880.00View SEC Filing  
1/3/2014David DavidsonInsiderSell15,000$20.88$313,200.00View SEC Filing  
1/3/2014Linda BainVPSell5,000$20.89$104,450.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

bluebird bio (NASDAQ BLUE) News Headlines

Source:
DateHeadline
Bluebird Up on Buyout Speculation After Celgene/Juno DealBluebird Up on Buyout Speculation After Celgene/Juno Deal
finance.yahoo.com - January 23 at 3:20 PM
Bluebird Bio Shouldnt Be Blue - BloombergBluebird Bio Shouldn't Be Blue - Bloomberg
www.bloomberg.com - January 22 at 3:21 PM
Bluebird Bio Shouldnt Be BlueBluebird Bio Shouldn't Be Blue
finance.yahoo.com - January 22 at 3:21 PM
Why bluebird bio Is Soaring 11.9% TodayWhy bluebird bio Is Soaring 11.9% Today
finance.yahoo.com - January 22 at 3:21 PM
bluebird bio (BLUE) Soars: Stock Adds 7.3% in Sessionbluebird bio (BLUE) Soars: Stock Adds 7.3% in Session
www.zacks.com - January 18 at 10:44 AM
Juno Therapeutics Surges on Report of Celgene Deal TalksJuno Therapeutics Surges on Report of Celgene Deal Talks
www.msn.com - January 17 at 9:40 AM
Could Little Known Orgenesis (ORGS) Become A Dominant Player in The Multi Billion Dollar Cell Therapy Market?Could Little Known Orgenesis (ORGS) Become A Dominant Player in The Multi Billion Dollar Cell Therapy Market?
finance.yahoo.com - January 17 at 9:40 AM
bluebird bio, Inc. (BLUE) Receives Average Rating of "Hold" from Brokeragesbluebird bio, Inc. (BLUE) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 16 at 12:40 PM
 Analysts Anticipate bluebird bio, Inc. (BLUE) Will Post Quarterly Sales of $7.20 Million Analysts Anticipate bluebird bio, Inc. (BLUE) Will Post Quarterly Sales of $7.20 Million
www.americanbankingnews.com - January 15 at 2:04 AM
Zacks: Brokerages Anticipate bluebird bio, Inc. (BLUE) to Post -$1.64 Earnings Per ShareZacks: Brokerages Anticipate bluebird bio, Inc. (BLUE) to Post -$1.64 Earnings Per Share
www.americanbankingnews.com - January 13 at 11:32 PM
Up 188.7%, Is bluebird bio. Stock Still a Strong Buy? - Motley FoolUp 188.7%, Is bluebird bio. Stock Still a Strong Buy? - Motley Fool
www.fool.com - January 12 at 4:53 PM
What bluebird bio Wants You to Know About Its Business - Motley FoolWhat bluebird bio Wants You to Know About Its Business - Motley Fool
www.fool.com - January 12 at 4:53 PM
ANALYSIS-Drugmakers see a pricing blueprint in an $850,000 gene therapyANALYSIS-Drugmakers see a pricing blueprint in an $850,000 gene therapy
www.cnbc.com - January 12 at 9:52 AM
What bluebird bio Wants You to Know About Its BusinessWhat bluebird bio Wants You to Know About Its Business
finance.yahoo.com - January 12 at 9:52 AM
Up 188.7%, Is bluebird bio. Stock Still a Strong Buy?Up 188.7%, Is bluebird bio. Stock Still a Strong Buy?
finance.yahoo.com - January 11 at 10:06 AM
Jason Cole Sells 1,129 Shares of bluebird bio, Inc. (BLUE) StockJason Cole Sells 1,129 Shares of bluebird bio, Inc. (BLUE) Stock
www.americanbankingnews.com - January 9 at 7:16 PM
bluebird bio, Inc. (BLUE) Insider David Davidson Sells 3,522 Sharesbluebird bio, Inc. (BLUE) Insider David Davidson Sells 3,522 Shares
www.americanbankingnews.com - January 9 at 6:52 PM
bluebird bio, Inc. (BLUE) CEO Sells $942,320.30 in Stockbluebird bio, Inc. (BLUE) CEO Sells $942,320.30 in Stock
www.americanbankingnews.com - January 9 at 6:50 PM
CORRECTED-Bluebird to seek approvals for three treatments by end of 2019CORRECTED-Bluebird to seek approvals for three treatments by end of 2019
www.cnbc.com - January 9 at 5:09 PM
Bluebird to seek approvals for three treatments by end of 2019Bluebird to seek approvals for three treatments by end of 2019
www.nasdaq.com - January 9 at 5:09 PM
bluebird bios (BLUE) Hold Rating Reaffirmed at Oppenheimerbluebird bio's (BLUE) Hold Rating Reaffirmed at Oppenheimer
www.americanbankingnews.com - January 9 at 1:38 PM
bluebird bio Announces Closing of Over-Allotment Option in Public Offering - Business Wire (press release)bluebird bio Announces Closing of Over-Allotment Option in Public Offering - Business Wire (press release)
www.businesswire.com - January 8 at 5:10 PM
bluebird bio Announces Closing of Over-Allotment Option in Public Offeringbluebird bio Announces Closing of Over-Allotment Option in Public Offering
finance.yahoo.com - January 8 at 5:10 PM
David Davidson Sells 6,000 Shares of bluebird bio, Inc. (BLUE) StockDavid Davidson Sells 6,000 Shares of bluebird bio, Inc. (BLUE) Stock
www.americanbankingnews.com - January 5 at 6:16 PM
bluebird bio Reaches Analyst Target Price - Nasdaqbluebird bio Reaches Analyst Target Price - Nasdaq
www.nasdaq.com - January 3 at 5:07 PM
Heres How bluebird bio, Inc. Crushed It in 2017Here's How bluebird bio, Inc. Crushed It in 2017
www.fool.com - January 2 at 4:29 PM
bluebird bio (BLUE) vs. The Competition Head-To-Head Surveybluebird bio (BLUE) vs. The Competition Head-To-Head Survey
www.americanbankingnews.com - December 31 at 7:30 AM
 Brokerages Anticipate bluebird bio, Inc. (BLUE) Will Announce Quarterly Sales of $7.20 Million Brokerages Anticipate bluebird bio, Inc. (BLUE) Will Announce Quarterly Sales of $7.20 Million
www.americanbankingnews.com - December 30 at 2:42 PM
-$1.64 Earnings Per Share Expected for bluebird bio, Inc. (BLUE) This Quarter-$1.64 Earnings Per Share Expected for bluebird bio, Inc. (BLUE) This Quarter
www.americanbankingnews.com - December 28 at 5:20 AM
Oppenheimer Weighs in on bluebird bio, Inc.s FY2017 Earnings (BLUE)Oppenheimer Weighs in on bluebird bio, Inc.'s FY2017 Earnings (BLUE)
www.americanbankingnews.com - December 25 at 3:28 AM
bluebird bio, Inc. (BLUE) Given Average Rating of "Hold" by Brokeragesbluebird bio, Inc. (BLUE) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 22 at 11:56 AM
Brokers Issue Forecasts for bluebird bio, Inc.s Q4 2017 Earnings (BLUE)Brokers Issue Forecasts for bluebird bio, Inc.'s Q4 2017 Earnings (BLUE)
www.americanbankingnews.com - December 22 at 9:22 AM
bluebird bio (BLUE) Now Covered by CIBCbluebird bio (BLUE) Now Covered by CIBC
www.americanbankingnews.com - December 21 at 5:12 PM
bluebird bio to Present at Investor Conferences in Januarybluebird bio to Present at Investor Conferences in January
finance.yahoo.com - December 21 at 5:06 PM
bluebird bio (BLUE) Receives New Coverage from Analysts at Oppenheimerbluebird bio (BLUE) Receives New Coverage from Analysts at Oppenheimer
www.americanbankingnews.com - December 20 at 7:20 PM
What to Expect From Celgene Corporation in 2018What to Expect From Celgene Corporation in 2018
finance.yahoo.com - December 20 at 9:52 AM
DURECT (DRRX) versus bluebird bio (BLUE) Head to Head ReviewDURECT (DRRX) versus bluebird bio (BLUE) Head to Head Review
www.americanbankingnews.com - December 19 at 7:10 AM
Bluebird Bio Inc (BLUE) President and CEO Nick Leschly Sold $21.6 million of SharesBluebird Bio Inc (BLUE) President and CEO Nick Leschly Sold $21.6 million of Shares
finance.yahoo.com - December 16 at 9:50 AM
bluebird bio, Inc. (BLUE) Insider Sells $21,629,400.00 in Stockbluebird bio, Inc. (BLUE) Insider Sells $21,629,400.00 in Stock
www.americanbankingnews.com - December 15 at 5:42 PM
Analyst Doubts Bluebird Bio Shares — Up 200% In 2017 — Can Fly Much Higher - BenzingaAnalyst Doubts Bluebird Bio Shares — Up 200% In 2017 — Can Fly Much Higher - Benzinga
www.benzinga.com - December 15 at 5:35 PM
Heres Why Everyones So Excited About bluebird bio - Motley FoolHere's Why Everyone's So Excited About bluebird bio - Motley Fool
www.fool.com - December 15 at 5:35 PM
Upcoming Conversation With An Expert: Highlights In CAR-T - Seeking AlphaUpcoming Conversation With An Expert: Highlights In CAR-T - Seeking Alpha
seekingalpha.com - December 15 at 5:35 PM
FY2017 EPS Estimates for bluebird bio, Inc. Lowered by Wedbush (BLUE)FY2017 EPS Estimates for bluebird bio, Inc. Lowered by Wedbush (BLUE)
www.americanbankingnews.com - December 14 at 8:14 AM
FY2019 EPS Estimates for bluebird bio, Inc. (BLUE) Increased by AnalystFY2019 EPS Estimates for bluebird bio, Inc. (BLUE) Increased by Analyst
www.americanbankingnews.com - December 13 at 11:28 PM
bluebird bio (BLUE) Receives Overweight Rating from Barclaysbluebird bio (BLUE) Receives Overweight Rating from Barclays
www.americanbankingnews.com - December 13 at 11:10 PM
bluebird bio, Inc. (BLUE) Insider Jeffrey T. Walsh Sells 9,900 Sharesbluebird bio, Inc. (BLUE) Insider Jeffrey T. Walsh Sells 9,900 Shares
www.americanbankingnews.com - December 13 at 5:26 PM
bluebird bio, Inc. (BLUE) Director Mark Vachon Sells 7,000 Sharesbluebird bio, Inc. (BLUE) Director Mark Vachon Sells 7,000 Shares
www.americanbankingnews.com - December 13 at 5:26 PM
bluebird bio (BLUE) Prices 3.24M Share Common Offering at $185/Shbluebird bio (BLUE) Prices 3.24M Share Common Offering at $185/Sh
www.streetinsider.com - December 13 at 5:13 PM
Analyst Doubts Bluebird Bio Shares — Up 200% In 2017 — Can Fly Much HigherAnalyst Doubts Bluebird Bio Shares — Up 200% In 2017 — Can Fly Much Higher
finance.yahoo.com - December 13 at 5:13 PM
Bluebird Bio Stumbles Over Secondary OfferingBluebird Bio Stumbles Over Secondary Offering
finance.yahoo.com - December 13 at 5:13 PM

SEC Filings

bluebird bio (NASDAQ:BLUE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

bluebird bio (NASDAQ:BLUE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

bluebird bio (NASDAQ BLUE) Stock Chart for Wednesday, January, 24, 2018

Loading chart…

This page was last updated on 1/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.